Abstract
Project Description
This triple analysis focuses on cancer drug development strategies in both
Breast Cancer and Lung Cancer and by the mechanism/target/effect of
Angiogenesis. Each of these three individual parts is evaluated according to
standardized criteria in a five pillar pipeline drug assessment methodology to
compare drug development strategies in oncology. This makes it easy to find
and compare analysis not only within one single cancer focus area but also
between different areas.
Below is a short synopsis of each part included in this report:
Part I: Breast Cancer
The breast cancer report part comprises defined and up to date development
strategies for 405 breast cancer drugs within the portfolio of 220
investigators, from Ceased to Marketed. This report part extensively analyses
207 identified targets of breast cancer drugs, organized into 193 drug target
strategies, and assesses them in breast cancer.
This part is based on the following publication:
Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is
Around the Corner in a Highly Competitive Market Place
Part II: Lung Cancer
The lung cancer report part comprises defined and up to date development
strategies for 416 lung cancer drugs within the portfolio of 218
investigators, from Ceased to Marketed. This part extensively analyses their
241 identified drug targets, organized into 237 drug target strategies, and
assesses them in eight different compound strategies and and three
subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from
Research To Market
Part III: Angiogenesis
The angiogenesis report part comprises defined and up to date development
strategies for 239 drugs affecting angiogenesis in oncology within the
portfolio of 148 investigators, from Preclinical to Marketed. This report part
extensively analyses 174 identified targets of angiogenesis affecting drugs,
organized into 167 drug target strategies, and assesses them in 64 different
cancer indications.
This part is based on the following publication:
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool
for Optimizing the Pipeline
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug' s properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Breast Cancer
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Breast Cancer Target for the Highest
Therapeutic Outcome and Return on Investment (207 Drug Targets)
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Strategies Identified in the Breast Cancer Therapeutic
Pipeline? (193 Drug Target Strategies and 405 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer
Drugs by Compound Strategy (8 Different Compound Strategies)
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of Breast
Cancer Therapeutic Pipeline by Investigator (220 Investigators)
- 11 Drug Index
- 12 Company Index
- Figures: Includes 7 Figures
- Tables: Includes 274 Tables
- Total Number of Pages: 913
Part II: Lung Cancer
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest
Therapeutic Outcome and Return on Investment (241 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target
Strategies and 416 Lung Cancer Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer
Drugs by Compound Strategy (8 Compound Strategies)
- 9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of
Lung Cancer)
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung
Cancer Drug Pipeline by Investigator (218 Companies)
- 11 Disclaimer
- 12 Drug Index
- 13 Company Index
- Figures: Includes 7 Figures
- Tables: Includes 284 Tables
- Total Number of Pages: 1323
Part III: Angiogenesis
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (174 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167
Drug Target Strategies and 239 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs
Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies)
- 9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in
Oncology (64 Cancer Indications)
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the
Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148
Investigators)
- 10 Disclaimer
- 11 Drug Index
- 12 Company Index
- Figures: Includes 7 Figures
- Tables: Includes 300 Tables
- Total Number of Pages: 1227
